Dr. Shmuel Cabilly holds a PhD in Immunology from the Hebrew University.
In the Backman Research Institute of the City of Hope he initiated the development of a new breakthrough technology for recombinant antibody production, which was patented and known as the “Cabilly Patent”.
Today, there are already more than 20 drugs in the market based on this technology, among which are Herceptin, Rituxan, Traceba, Raptiva, Xolair and others.
Dr. Cabilly was also a co-founder and a Chief Scientist of Ethrog Biotechnology, where he invented dry buffer technologies enabling the production of a liquid free disposable apparatus for gel electrophoresis and a technology that enables the condensation of molecular separation zones to a small gel area. This technology was sold to Invitrogen in 2001. Dr. Cabilly is now an investor and serves as a board member of several companies.